Poems

A FINE NIGHT IN THE CITY, TAKING DOWN CHRISTMAS DECORATIONS, POSITIONING, THE SEVENTH DECADE, SHE, AUTUMN IN CANAD

SQUARE-DANCE THEME 1 & 2

You, Clara Eliza, five-foot legendary grandmother, battling wood fires in a freezing daw

Why I Write

My primary impulse is a private, individual one- a powerful urge to say the unsayable; this is one of the ways in which I think of poetry, its purpose and function. The desire to make sense of the amorphous and chaotic experience of living is part of this; I can\u27t do better than quote Picasso: \u27Art stabilises us on the edge of chaos\u27. From as far back as I can remember in my growing up, the way to \u27make sense\u27 was through words, so I have a lifelong passion for the power and intricacies of language. I write to discover, not to tell what I know. The flash of something new (even if in one sense familiar) is where a poem begins; the writing of the poem elucidates for me what that first glimpse meant

Poems

RHINELAND, CITY LIGHTS, ECHOES, THE NIGHT BURNS WITH A WHITE FIRE, THINGS, SUMMER NEAR THE ARCTIC CIRCL

Therapy Related Myeloid Neoplasms Following PARP Inhibitors: Real-Life Experience.

International audiencePURPOSE: To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi). EXPERIMENTAL DESIGN: In a French cancer center, we identified and described the profiles of 13 t-MN diagnosed among 37 ovarian cancer (OC) patients referred to hematology consultation for cytopenia under PARPi. Next, we described these 13 t-MN post PARPi among 37 t-MN post OC according to PARPi exposure. Finally, we described 69 t-MN post PARPi in a national cohort. RESULTS: From 2016 to 2021, cumulative incidence of t-MN was 3.5% (13/373) among OC patients treated with PARPi. At time of hematological consultation, patients with t-MN had a longer PARPi exposure (9 months vs. 3, p= 0.01), lower platelet count (74 vs. 173 G/L, p=0.0005), and more cytopenias (2 vs. 1, p=0.0005). Compared to t-MN not exposed to PARPi, t-MN-PARPi patients had more BRCA1/2 germline mutation (61.5% vs. 0% p=0.03) but similar OS. In the national cohort, most t-MN post PARPi had a complex karyotype (61%) associated with a high rate of TP53 mutation (71%). Median OS was 9.6 months (IQR, 4-14.6). In multivariate analysis, a longer time between end of PARPi and t-MN (HR 1.046, p=0.02), olaparib compared to others PARPi (HR 5.82, p=0.003) and AML (HR 2.485, p=0.01) were associated with shorter OS. CONCLUSIONS: In a large series, we described a high incidence of t-MN post PARPi associated with unfavorable cytogenetic and molecular abnormalities leading to poor OS. Early detection is crucial, particularly in cases of delayed cytopenia